[NH2:1][C:2]1[N:7]=[CH:6][N:5]=[C:4]2[N:8]([CH:31]3[CH2:36][CH2:35][N:34]([CH:37]4[CH2:42][CH2:41][N:40]([CH3:43])[CH2:39][CH2:38]4)[CH2:33][CH2:32]3)[N:9]=[C:10]([C:11]3[CH:16]=[CH:15][C:14]([NH:17][C:18]([C@@H:20]4[CH2:22][C@H:21]4[C:23]4[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=4)=[O:19])=[C:13]([O:29][CH3:30])[CH:12]=3)[C:3]=12.[C:44]([OH:51])(=[O:50])/[CH:45]=[CH:46]\[C:47]([OH:49])=[O:48]>C(O)C>[C:44]([OH:51])(=[O:50])/[CH:45]=[CH:46]\[C:47]([OH:49])=[O:48].[C:44]([OH:51])(=[O:50])/[CH:45]=[CH:46]\[C:47]([OH:49])=[O:48].[NH2:1][C:2]1[N:7]=[CH:6][N:5]=[C:4]2[N:8]([CH:31]3[CH2:32][CH2:33][N:34]([CH:37]4[CH2:42][CH2:41][N:40]([CH3:43])[CH2:39][CH2:38]4)[CH2:35][CH2:36]3)[N:9]=[C:10]([C:11]3[CH:16]=[CH:15][C:14]([NH:17][C:18]([C@@H:20]4[CH2:22][C@H:21]4[C:23]4[CH:24]=[CH:25][CH:26]=[CH:27][CH:28]=4)=[O:19])=[C:13]([O:29][CH3:30])[CH:12]=3)[C:3]=12N1-{4-[4-amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl}-trans-2-phenylcyclopropane-1-carboxamide (75 mg, 0.129 mmol) was dissolved in ethanol (2 mL) and maleic acid (45 mg, 0.387 mmol) in ethanol (1 mL) was added. The reaction mixture was stirred at room temperature for 5 hours. The solvent was removed and ethyl acetate was added and the solid was collected by filtration to give N1-{4-[4-amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl}-trans-2-phenylcyclopropane-1-carboxamide, dimaleate salt (75 mg). 1H NMR (DMSO-d6) δ 1.17 (m, 1H), 1.32 (m, 2H), 1.48 (m, 2H), 1.48, (m, 2H), 2.19 (m, 4H), 2.37 (M, 1H), 2.46 (m, 1H), 2.59 (m, 1H), 2.78 (s, 3H), 2.98-3.52 (bm, 9H), 3.90 (s, 3H), 5.02 (m, 1H), 6.08 (s, 4H), 7.17-7.33 (m, 7H), 8.25 (m, 2H), 9.65 (s, 1H). LCMS (Finigan-Column: Pecosphere, C18, 3 um, 33×4.6 mm. Eluents: 0% B/A to 100% B/A in 4 min. (B: acetonitrile, A: 50 mM ammonia acetate buffer, pH 4.5), 3.0 mL/min.): MH+=581.4, Rt=1.77 min.